News Center American Regent is a leading manufacturer and marketer of generic and branded specialty injectables. We have been able to achieve an admirable level of success, not only due to our own initiatives, but also because of the success of strategic partnerships.

American Regent Announces Enrollment of First Patient in Phase 3 Trial to Investigate Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency
Shirley, NY (April, 24, 2017) – American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3 clinical trial, HEART-FID. This double-blind, multicenter, prospective, randomized, placebo-controlled study will assess the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of patients with heart failure, iron deficiency and a reduced ejection fraction.
Read the full press release

American Regent announces the commercial availability of Busulfan Injection, the first and only AP-rated therapeutically equivalent generic to Busulfex®
Shirley, NY (March 1, 2017) - American Regent today announced the launch of Busulfan Injection which had been previously approved by the U.S. Food and Drug Administration.
Read the press release







© 2017, American Regent, Inc., A Luitpold Pharmaceuticals, Inc. Company
PP-AS-US-0014     4/2017